Ted Myles, MBA

Ted Myles has served as Chief Operating Officer & Chief Financial Officer of Scholar Rock since January 2022. Prior to joining Scholar Rock in July 2020 as Chief Financial Officer & Head of Business Operations, he served as a member of the company’s board of directors from November 2018 until July 2020. Previously, Ted served as Chief Financial Officer and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage bio-pharmaceutical company (acquired by Covis Pharmaceuticals). Prior to AMAG, he served as Chief Financial Officer and Chief Operating Officer at Ocata Therapeutics, Inc. (acquired by Astellas), Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. (acquired by Qiagen), and Controller of EMD Pharmaceuticals (now EMD Serono, a part of Merck KGaA). Earlier in his career, Ted was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and was a senior associate in the audit practice of Coopers & Lybrand LLP. He holds an MBA from John M. Olin School of Business at Washington University and a B.S. in Business Administration from the University of Hartford. Since July 2024, Ted has served on the board of directors of Full-Life Technologies, a fully integrated global radiotherapeutics company. Ted serves as chairman of the audit committee and a member of the compensation committee.